BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 29948566)

  • 1. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
    Bresalier RS
    Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
    Wang F; Lv ZS; Fu YK
    Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Status of Chemoprevention in Barrett's Esophagus.
    Moayyedi P; El-Serag HB
    Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention in Barrett's oesophagus.
    Baruah A; Buttar NS
    Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):151-65. PubMed ID: 25743463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett's Esophagus.
    Shah SL; Dunbar K
    Curr Gastroenterol Rep; 2023 Dec; 25(12):374-379. PubMed ID: 37940812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
    Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
    Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
    Thrift AP
    Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemoprevention in adenocarcinoma of the esophagus].
    Lanas A; Alcedo González J
    Acta Gastroenterol Latinoam; 2007 Mar; 37(1):37-48. PubMed ID: 17486744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
    Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
    Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
    Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
    Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
    Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
    Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's oesophagus: Current controversies.
    Amadi C; Gatenby P
    World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medical treatment of Barrett's esophagus].
    Kinoshita Y; Yuki T
    Nihon Rinsho; 2005 Aug; 63(8):1449-53. PubMed ID: 16101238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?
    Akın H; Aydın Y
    Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S31-S32. PubMed ID: 29199164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
    Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
    Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.